HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Myelodysplastic syndromes"

The IDMC ( Independent Data Monitoring Committee ) found a statistically significant improvement in time to disease progression in patients with multiple myeloma receiving Lenalidomide ( Revlimid ) pl ...


A multicenter Phase II trial, MDS-002, showed that Revlimid ( Lenalidomide ) is active in a larger group of patients with low and intermediate-1 risk myelodysplastic syndromes ( MDS ), who lack a dist ...


Blood Products Advisory Committee ( BPAC ) of the FDA ( Food and Drug Administration ) has given a positive review of Exjade ( Deferasirox ). Exjade is once-daily oral iron chelator for the trea ...


Interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp ( Darbepoetin alfa ) administered every three weeks to treat anemia in patients with a bone marrow disorder known as myelodys ...


A subset analysis of the international phase III trial ( AZA-001 ) has demonstrated that the overall survival benefit observed in higher-risk myelodysplastic syndromes ( MDS ) patients extended to pat ...


A subset analysis of the international phase III trial ( AZA-001 ) has demonstrated that the overall survival benefit observed in higher-risk myelodysplastic syndromes ( MDS ) patients extended to pat ...


The results from AZA-001 are published in The Lancet Oncology. The data indicate that Vidaza ( Azacitidine ) demonstrated a significant extension of overall survival compared to conventional care regi ...


Beta-thalassemias are characterized by ineffective red blood cell ( RBC ) production, leading to anemia, iron overload, and organ failure. As current treatment options for beta-thalassemia are limited ...


Results from THALASSA, the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade ( Deferasirox ) in patients with non-transfusion-dependent thalassemia ( NTDT ), w ...


Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


The benefit of Azacitidine treatment in survival of high-risk myelodysplastic syndromes ( MDS ) patients compared with conventional care treatment ( CCT ) has not been established outside clinical tri ...


Outcomes of patients with myelodysplastic syndromes ( MDS ) after hypomethylating agent ( HMA ) failure remain poor. Improving the response and survival of patients with higher-risk myelodysplastic sy ...